Clinical Trials
152 trialsMK-3475-06C
Merck Sharp & Dohme LLC
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
University of Washington
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
OrigAMI-1
Janssen Research & Development, LLC
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
PANGEA
UNC Lineberger Comprehensive Cancer Center
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
iintune-1
Takeda
MK-3475-06E
Merck Sharp & Dohme LLC
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Akeso
Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
Mayo Clinic
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
MK-9999-02A
Merck Sharp & Dohme LLC
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Zhejiang Doer Biologics Co., Ltd.
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Georgetown University
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Thomas Jefferson University
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
BeiGene
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Chang Gung Memorial Hospital
Establishing Best Treatment Strategy for T4 Esophageal Cancer
National Cheng-Kung University Hospital
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Pharma
HAICI
Zhejiang Cancer Hospital
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Fujian Cancer Hospital
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
ImmunityBio, Inc.
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
ImmunityBio, Inc.
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.